Prognostic nutritional index is superior to neutrophil-tolymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin

20Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) are prognostic markers for operable breast cancer. However, their importance in patients with metastatic breast cancer (MBC) remains unclear. This study aimed to evaluate these parameters as prognostic markers in MBC patients treated with eribulin. Patients and Methods: A total of 60 patients with MBC treated with eribulin were included. Results: Although high PNI and low NLR were correlated with better progression-free survival (PFS) and overall survival (OS), PNI had stronger impact as prognostic marker than NLR (PNI: HR=0.35, p=0.0008 for PFS and HR=0.27, p=0.0068 for OS; NLR: HR=0.71, p=0.081 for PFS and HR=0.63, p=0.14 for OS). Multivariate analysis demonstrated that PNI was an independent predictor of PFS (HR=0.30, p=0.0009). Conclusion: PNI could be a more reliable prognostic marker for MBC patients treated with eribulin than NLR.

Cite

CITATION STYLE

APA

OBA, T., MAENO, K., ONO, M., ITO, T., KANAI, T., & ITO, K. I. (2021). Prognostic nutritional index is superior to neutrophil-tolymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin. Anticancer Research, 41(1), 445–452. https://doi.org/10.21873/anticanres.14794

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free